Want to see HK:2315 full AI Analyst Report?
Top Page
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
(2315)
Select Model
Select Model
Rating:56Neutral
Price Target:
HK$39.00
▲(35.89% Upside)
Action:Reiterated
Date:10/31/26
The score is anchored by improved fundamentals (profitability and positive cash generation in 2024–2025), but is held back by very weak technicals (price far below key moving averages with negative MACD) and a relatively high P/E with no dividend yield data to offset valuation risk.
Positive Factors
Revenue Scaling
Revenue has expanded substantially over multiple years, demonstrating increasing commercial scale across the company’s antibody discovery and preclinical research activities. Continued growth supports operating leverage, broadens the platform’s market reach, and provides a stronger base for future partnerships and asset monetization.
Negative Factors
Profitability Durability
Although profitability improved sharply, the recent history of deep losses means the earnings inflection has not yet been demonstrated across a long operating cycle. Sustained execution is required to show that current margins can persist through changes in program mix and research investment.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scaling
Revenue has expanded substantially over multiple years, demonstrating increasing commercial scale across the company’s antibody discovery and preclinical research activities. Continued growth supports operating leverage, broadens the platform’s market reach, and provides a stronger base for future partnerships and asset monetization.
Read all positive factors
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H (2315) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$17.02B
Dividend YieldN/A
Average Volume (3M)2.14M
Price to Earnings (P/E)38.2
Beta (1Y)0.69
Revenue Growth48.04%
EPS Growth166.72%
CountryHK
Employees1,443
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.85
Shares Outstanding110,781,920
10 Day Avg. Volume2,280,071
30 Day Avg. Volume2,138,265
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)5.83
Price to Sales (P/S)9.20
P/FCF Ratio44.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.8
Revenue Forecast (FY)HK$1.93B
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., established in 2009 with its main office in Beijing, China, operates as a global biotechnology firm. Its core business involves the international research and development of antibody-based treatments...
How the Company Makes Money
The company primarily makes money by providing technology- and research-based services and by monetizing antibody assets. Key revenue streams include: (1) service income from preclinical R&D and antibody discovery activities enabled by its proprie...
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
70
Positive
Cash Flow
66
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.70B | 1.38B | 980.45M | 716.91M | 533.88M | 354.56M |
| Gross Profit | 1.31B | 1.05B | 761.52M | 506.03M | 391.75M | 247.44M |
| EBITDA | 585.05M | 419.49M | 303.80M | -97.87M | -430.50M | -378.12M |
| Net Income | 366.30M | 173.20M | 33.54M | -382.95M | -602.16M | -545.58M |
Balance Sheet | ||||||
| Total Assets | 3.64B | 3.72B | 2.42B | 2.45B | 2.80B | 2.30B |
| Cash, Cash Equivalents and Short-Term Investments | 1.04B | 1.56B | 381.18M | 408.09M | 611.27M | 566.45M |
| Total Debt | 869.00M | 584.09M | 570.28M | 544.11M | 415.28M | 89.80M |
| Total Liabilities | 1.22B | 1.54B | 1.58B | 1.66B | 1.65B | 1.05B |
| Stockholders Equity | 2.42B | 2.17B | 834.06M | 785.89M | 1.15B | 1.25B |
Cash Flow | ||||||
| Free Cash Flow | 137.75M | 282.43M | 174.12M | -203.26M | -543.94M | -564.45M |
| Operating Cash Flow | 411.09M | 370.25M | 211.25M | -76.65M | -303.27M | -365.78M |
| Investing Cash Flow | -543.34M | -184.86M | -137.12M | -100.28M | -153.74M | -84.13M |
| Financing Cash Flow | 548.82M | 979.86M | -92.03M | -37.82M | 587.20M | 219.44M |
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Technical Analysis
Negative
28.70
Price Trends
59.07
Negative
55.14
Negative
52.89
Negative
Market Momentum
-6.57
Positive
29.68
Positive
19.90
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2315, the sentiment is Negative. The current price of 28.7 is below the 20-day moving average (MA) of 54.19, below the 50-day MA of 59.07, and below the 200-day MA of 52.89, indicating a bearish trend. The MACD of -6.57 indicates Positive momentum. The RSI at 29.68 is Positive, neither overbought nor oversold. The STOCH value of 19.90 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2315.
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$183.11B | 31.19 | 10.51% | ― | 21.93% | 21.94% | |
66 Neutral | HK$51.82B | 7.90 | 105.60% | ― | 292.84% | ― | |
64 Neutral | HK$79.58B | -14.95 | -16.23% | 0.35% | 53.48% | -120.02% | |
60 Neutral | HK$26.75B | 26.18 | 20.41% | ― | 32.63% | 8.74% | |
56 Neutral | HK$17.02B | 38.23 | 15.94% | ― | 48.04% | 166.72% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | HK$30.07B | -69.15 | -7.23% | ― | 35.82% | 54.40% |
* Healthcare Sector Average
HK:2315
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H
38.30
9.06
30.98%
HK:1548
Genscript Biotech
35.02
17.98
105.52%
HK:2269
Wuxi Biologics (Cayman)
44.48
8.86
24.87%
HK:9995
RemeGen Co. Ltd. Class H
64.85
-28.00
-30.16%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
15.26
-11.44
-42.85%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
49.06
-20.04
-29.00%
Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H Corporate Events
Biocytogen Posts Strong Nine-Month Revenue and Profit Growth in Unaudited Q3 Update
Oct 29, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a dual-listed Chinese biopharmaceutical group trading in Hong Kong and on Shanghai’s STAR Market, reported its financials for the nine months ended September 30, 2026 under PRC accounting stand...
Biocytogen Sets Board Meeting to Approve Third-Quarter 2026 Results
Oct 16, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a PRC-incorporated pharmaceutical and biotechnology company listed in Hong Kong, focuses on developing and commercializing healthcare and drug-related innovations. Its board structure blends executiv...
Biocytogen Shareholders Approve Change to Proceeds-Funded Project at Hybrid EGM
Sep 16, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a Hong Kong-listed biopharmaceutical company with both H and A shares, convened its 2026 third extraordinary general meeting in a hybrid format in Beijing and online. The meeting was attended by 180 ...
Biocytogen Calls 2026 Extraordinary Meeting on Proceeds-Funded Project Change
Aug 27, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has convened its 2026 third extraordinary general meeting for 2:00 p.m. on September 16, 2026, in a hybrid physical and virtual format in Beijing and online. The meeting will ask shareholders to consi...
Biocytogen Pharmaceuticals to Publish 2026 Interim Report for H Shares
Aug 27, 2026
Biocytogen Pharmaceuticals (Beijing) Co. Ltd., a Hong Kong-listed Chinese biopharmaceutical group, has released unaudited interim results for the six months ended 30 June 2026. The H share issuer operates under Hong Kong Stock Exchange rules, with...
Biocytogen schedules August board meeting to review interim results and dividend
Aug 17, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. has scheduled a board meeting for 27 August 2026 to review and approve the interim results for the six months ended 30 June 2026. The board will also consider the potential declaration of an interim d...
Biocytogen forecasts strong interim 2026 surge driven by scale and innovation
Aug 6, 2026
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. expects a sharp improvement in its interim 2026 performance, with unaudited revenue for the first half projected between RMB936.4 million and RMB946.4 million, reflecting year-on-year growth of about ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.